<?xml version="1.0" encoding="UTF-8"?>
<ref id="B14-biomedicines-08-00060">
 <label>14.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ribas</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Puzanov</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Dummer</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Schadendorf</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Hamid</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Robert</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Hodi</surname>
    <given-names>F.S.</given-names>
   </name>
   <name>
    <surname>Schachter</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Pavlick</surname>
    <given-names>A.C.</given-names>
   </name>
   <name>
    <surname>Lewis</surname>
    <given-names>K.D.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (Keynote-002): A randomised, controlled, phase 2 trial</article-title>
  <source>Lancet Oncol.</source>
  <year>2015</year>
  <volume>16</volume>
  <fpage>908</fpage>
  <lpage>918</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(15)00083-2</pub-id>
  <pub-id pub-id-type="pmid">26115796</pub-id>
 </element-citation>
</ref>
